Post by The Pharma Navigator

3,229 followers

๐๐ฎ๐ญ๐ญ๐ข๐ง๐  ๐š ๐’๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ง ๐…๐จ๐ซ๐ฆ๐ฎ๐ฅ๐š๐ญ๐ข๐จ๐ง ๐’๐ž๐ซ๐ฏ๐ข๐œ๐ž๐ฌ The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements. Featuring: Owen Murray, CEO at Bend Bioscience, Armin Spura, CEO at BioDuro, Greg Behar, CEO at Recipharm, Rod Ketner, Vice President, Business Operations at Serรกn BioScience, and many more. Read the full article here ๐Ÿ‘‰ https://lnkd.in/em9jz4_X

Post content